The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in patients with advanced solid cancers: Study design and rationale.
 
Omar Saavedra Santa Gadea
No Relationships to Disclose
 
Elena Garralda
Consulting or Advisory Role - Alkermes; Anaveon; Boehringer Ingelheim; Bristol-Myers Squibb; Ellipses Pharma; F-Star Therapeutics; Hengrui Therapeutics; Janssen; MAB Discovery; NeoMed; Roche; Seagen; Thermo Fisher Scientific
Speakers' Bureau - Lilly; MSD; Novartis; Roche; Thermo Fisher Scientific
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); BioNTech (Inst); Catalym (Inst); CytomX Therapeutics (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Ribon Therapeutics (Inst); Roche (Inst); Seagen (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst)
 
Juanita Suzanne Lopez
Consulting or Advisory Role - Basilea; Genmab; Novartis
Research Funding - Astex Pharmaceuticals (Inst); Basilea (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Basilea; Roche/Genentech
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Archer; ARIAD; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; EMD Serono; Foundation Medicine; Genentech; Gilead Sciences; Gritstone Bio; Hengrui Therapeutics; Instil Bio; Janssen Oncology; Maverick Therapeutics; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Panasonic; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)
 
Jacob Stephen Thomas
No Relationships to Disclose
 
Crescens Diane Tiu
No Relationships to Disclose
 
Daniela Morales-Espinosa
Employment - Affimed Therapeutics
Stock and Other Ownership Interests - Novartis (I); Pfizer (I); Procter & Gamble (I); Roche (I)
Consulting or Advisory Role - Takeda
 
Christa Raab
Employment - Affimed Therapeutics
Stock and Other Ownership Interests - Affimed Therapeutics
 
Bettina Rehbein
Employment - Affimed Therapeutics
Stock and Other Ownership Interests - Novartis
 
Gabriele Hintzen
Employment - Affimed Therapeutics
Stock and Other Ownership Interests - Affimed Therapeutics; Novartis
 
Kerstin Pietzko
Employment - Affimed Therapeutics
Stock and Other Ownership Interests - Affimed Therapeutics
 
Paulien Ravenstijn
Employment - Affimed Therapeutics
 
Michael Emig
Employment - Affimed Therapeutics; Lilly; Merck KGaA
Stock and Other Ownership Interests - Lilly
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Roche/Genentech; SERVIER; Tallac Therapeutics
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Roche; SERVIER; Tallac Therapeutics
Research Funding - Astex Pharmaceuticals; AstraZeneca; Fulgent Genetics